Jane Street’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.4M | Sell |
748,949
-752,168
| -50% | -$24.2M | ﹤0.01% | 1612 |
|
|
2025
Q4 | $52.8M | Buy |
1,501,117
+707,311
| +89% | +$25.1M | 0.01% | 904 |
|
|
2025
Q3 | $20.9M | Buy |
793,806
+61,632
| +8% | +$1.84M | ﹤0.01% | 1630 |
|
|
2025
Q2 | $19.4M | Buy |
732,174
+545,528
| +292% | +$14.4M | ﹤0.01% | 1475 |
|
|
2025
Q1 | $4.51M | Sell |
186,646
-221,033
| -54% | -$6.99M | ﹤0.01% | 3085 |
|
|
2024
Q4 | $16.4M | Buy |
407,679
+68,872
| +20% | +$3.93M | ﹤0.01% | 1429 |
|
|
2024
Q3 | $21.4M | Sell |
338,807
-44,525
| -12% | -$2.61M | ﹤0.01% | 1191 |
|
|
2024
Q2 | $20.3M | Buy |
383,332
+36,244
| +10% | +$2.38M | ﹤0.01% | 1305 |
|
|
2024
Q1 | $28.5M | Sell |
347,088
-3,152
| -0.9% | -$140K | 0.01% | 949 |
|
|
2023
Q4 | $6.52M | Buy |
350,240
+97,241
| +38% | +$1.27M | ﹤0.01% | 2490 |
|
|
2023
Q3 | $2.8M | Sell |
252,999
-289,071
| -53% | -$4.13M | ﹤0.01% | 3479 |
|
|
2023
Q2 | $8.79M | Buy |
542,070
+184,425
| +52% | +$3.86M | ﹤0.01% | 2041 |
|
|
2023
Q1 | $5.95M | Buy |
357,645
+299,830
| +519% | +$3.1M | ﹤0.01% | 2204 |
|
|
2022
Q4 | $543K | Buy |
57,815
+44,908
| +348% | +$200K | ﹤0.01% | 5981 |
|
|
2022
Q3 | $36K | Sell |
12,907
-15,734
| -55% | -$51.5K | ﹤0.01% | 9044 |
|
|
2022
Q2 | $83K | Sell |
28,641
-12,217
| -30% | -$30.2K | ﹤0.01% | 8743 |
|
|
2022
Q1 | $123K | Buy |
40,858
+18,225
| +81% | +$65.4K | ﹤0.01% | 9350 |
|
|
2021
Q4 | $104K | Sell |
22,633
-7,904
| -26% | -$44.3K | ﹤0.01% | 9234 |
|
|
2021
Q3 | $192K | Buy |
+30,537
| New | +$189K | ﹤0.01% | 8878 |
|
|
2021
Q2 | – | Sell |
-73,941
| Closed | -$439K | – | 10472 |
|
|
2021
Q1 | $467K | Buy |
73,941
+41,983
| +131% | +$295K | ﹤0.01% | 6929 |
|
|
2020
Q4 | $180K | Sell |
31,958
-3,533
| -10% | -$21.4K | ﹤0.01% | 6999 |
|
|
2020
Q3 | $207K | Buy |
35,491
+23,503
| +196% | +$162K | ﹤0.01% | 6396 |
|
|
2020
Q2 | $86K | Sell |
11,988
-1,967
| -14% | -$13.1K | ﹤0.01% | 6761 |
|
|
2020
Q1 | $65K | Buy |
13,955
+2,322
| +20% | +$14.3K | ﹤0.01% | 5054 |
|
|
2019
Q4 | $93K | Sell |
11,633
-12,178
| -51% | -$88.8K | ﹤0.01% | 4858 |
|
|
2019
Q3 | $164K | Buy |
23,811
+286
| +1% | +$2.12K | ﹤0.01% | 4703 |
|
|
2019
Q2 | $196K | Sell |
23,525
-125,862
| -84% | -$1.08M | ﹤0.01% | 4698 |
|
|
2019
Q1 | $1.49M | Buy |
+149,387
| New | +$1.25M | ﹤0.01% | 2346 |
|
|
2018
Q4 | – | Sell |
-128,065
| Closed | -$1.53M | – | 5776 |
|
|
2018
Q3 | $2.23M | Buy |
+128,065
| New | +$1.52M | ﹤0.01% | 1792 |
|
Other funds holding VKTX
VCM
VPM
Jane Street's VKTX Position: Q1 2026 in Review
Jane Street reduced its Viking Therapeutics (VKTX) stake by 50% in Q1 2026, selling an estimated $24.2M and leaving 748,949 shares worth $24.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1612.
Jane Street first reported a position in VKTX in Q3 2018 and has held it in 29 quarters since. The position peaked at $52.8M in Q4 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Jane Street held 748,949 shares of Viking Therapeutics worth $24.4M as of Q1 2026.
- Jane Street sold 752,168 Viking Therapeutics shares in Q1 2026, an estimated $24.2M.
- Viking Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #1612 holding.
- Jane Street first reported a position in Viking Therapeutics in Q3 2018 and has held it in 29 quarters since.
- Jane Street's Viking Therapeutics position peaked at $52.8M in Q4 2025.
- 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.